Factor XIII Val34Leu polymorphism and risk of recurrent pregnancy loss in Iranian population: a case control study

Abstract

BACKGROUND: Recurrent pregnancy loss (RPL) is a heterogeneous condition and thrombophilias have been considered as a probable cause.

OBJECTIVE: The aim of this study was to investigate the prevalence of the coagulation factor XIII Val34Leu polymorphism among women with unexplained RPL.

METHODS: A total of 140 women with a history of unexplained RPL and 100 age-matched healthy fertile women were recruited. The presence of FXIII Val34Leu polymorphism among the cases and controls was investigated using PCR-RFLP method.

RESULTS: Genotype analyses of the subjects revealed that the patients had a significantly higher prevalence of V/L and L/L than the controls (P<0.05): 33.5% vs. 15%, and 9.2% vs. 2%, respectively.

CONCLUSION: These results indicate a significant association between FXIII Val34Leu polymorphism and unexplained RPL in the Iranian patient.

Keywords

factor XIII / Iranian population / recurrent pregnancy loss / Val34Leu polymorphism

References

[1] Aarabi M, Memariani T, Arefi S, Aarabi M, Hantoosh Zadeh S, Akhondi M A, Modarressi M H (2011). Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion. J Matern Fetal Neonatal Med, 24(3): 545–548

[2] Ariëns R A, Philippou H, Nagaswami C, Weisel J W, Lane D A, Grant P J (2000). The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood, 96(3): 988–995

[3] Bagheri M, Rad I A, Omrani M D, Nanbaksh F (2011). The Val34Leu genetic variation in the A subunit of coagulation factor XIII in recurrent spontaneous abortion. Syst Biol Reprod Med, 57(5): 261–264

[4] Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L (2012). Factor XIII, clot structure, thrombosis. Thromb Res, 129(3): 382–387

[5] Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona E, Komáromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L (2000). Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood, 96(7): 2479–2486

[6] Barbosa H C, Carvalho E C, Barini R, Siqueira L H, Costa D S, Annichino-Bizzacchi J M (2004). Tyr204Phe and Val34Leu polymorphisms in two Brazilian ethnic groups and in patients with recurrent miscarriages. Fertil Steril, 82(5): 1455–1457

[7] Brenner B (2002). Thrombophilia and pregnancy loss. Thromb Res, 108(4): 197–202

[8] Calderwood C J, Thanoon O I (2009). Thromboembolism and thrombophilia in pregnancy. Obstetrics, Gynaecol Reprod Med, 19(12): 339–343

[9] Catto A J, Kohler H P, Coore J, Mansfield M W, Stickland M H, Grant P J (1999). Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood, 93(3): 906–908

[10] Coulam C B, Jeyendran R S, Fishel L A, Roussev R (2006). Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol, 55(5): 360–368

[11] de Jong P G, Goddijn M, Middeldorp S (2011). Testing for inherited thrombophilia in recurrent miscarriage. Semin Reprod Med, 29(6): 540–547

[12] de Lange M, Andrew T, Snieder H, Ge D, Futers T S, Standeven K, Spector T D, Grant P J, Ariëns R A (2006). Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus. Arterioscler Thromb Vasc Biol, 26(8): 1914–1919

[13] Diz-Kucukkaya R, Hancer V S, Inanc M, Nalcaci M, Pekcelen Y (2004). Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus, 13(1): 32–35

[14] Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, Oberkanins C, Moritz A, Krugluger W, Huber J, Hopmeier P (2003). Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem, 49(7): 1081–1086

[15] Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P (2000). The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood, 95(2): 586–591

[16] Finan R R, Tamim H, Ameen G, Sharida H E, Rashid M, Almawi W Y (2002). Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol, 71(4): 300–305

[17] Francis C W (2002). Factor XIII polymorphisms and venous thromboembolism. Arch Pathol Lab Med, 126(11): 1391–1393

[18] Franco R F, Reitsma P H, Lourenço D, Maffei F H, Morelli V, Tavella M H, Araújo A G, Piccinato C E, Zago M A (1999). Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost, 81(5): 676–679

[19] Goodman C S, Coulam C B, Jeyendran R S, Acosta V A, Roussev R (2006). Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss? Am J Reprod Immunol, 56(4): 230–236

[20] Hancer V S, Diz-Kucukkaya R, Bilge A K, Ozben B, Oncul A, Ergen G, Nalcaci M (2006). The association between factor XIII Val34Leu polymorphism and early myocardial infarction. Circ J, 70(3): 239–242

[21] Hayano Y, Imai N, Karasawa T (1982) .Studies on the physiological changes of blood coagulation factor XIII during pregnancy and their significance (author's transl). Nihon Sanka Fujinka Gakkai Zasshi, 34(4): 469–477

[22] Jeddi-Tehrani M, Torabi R, Mohammadzadeh A, Arefi S, Keramatipour M, Zeraati H, Zarnani A H, Akhondi M M, Mahmoudian J, Mahmoudi A R, Zarei S (2010). Investigating association of three polymorphisms of coagulation factor XIII and recurrent pregnancy loss. Am J Reprod Immunol, 64(3): 212–217

[23] Kangsadalampai S, Board P G (1998). The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood, 92(8): 2766–2770

[24] Khalid A S, Joyce C, O’Donoghue K (2013). Prevalence of subclinical and undiagnosed overt hypothyroidism in a pregnancy loss clinic. Ir Med J, 106(4): 107–110

[25] Kovalevsky G, Gracia C R, Berlin J A, Sammel M D, Barnhart K T (2004). Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med, 164(5): 558–563

[26] López Ramírez Y, Vivenes M, Miller A, Pulido A, López Mora J, Arocha-Piñango C L, Marchi R (2006). Prevalence of the coagulation factor XIII polymorphism Val34Leu in women with recurrent miscarriage. Clin Chim Acta, 374(1-2): 69–74

[27] Madjunkova S, Volk M, Peterlin B, Plaseska-Karanfilska D (2012). Detection of thrombophilic mutations related to spontaneous abortions by a multiplex SNaPshot method. Genet Test Mol Biomarkers, 16(4): 259–264

[28] McCormack L J, Kain K, Catto A J, Kohler H P, Stickland M H, Grant P J (1998). Prevalence of FXIII V34L in populations with different cardiovascular risk. Thromb Haemost, 80(3): 523–524

[29] Mikkola H, Syrjälä M, Rasi V, Vahtera E, Hämäläinen E, Peltonen L, Palotie A (1994). Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood, 84(2): 517–525

[30] Muszbek L, Bagoly Z, Bereczky Z, Katona E ( 2008). The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem, 6(3):190–205

[31] Nelen W L, Blom H J, Steegers E A, den Heijer M, Eskes T K (2000). Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril, 74(6): 1196–1199

[32] Ozdemir O, Yenicesu G I, Silan F, Köksal B, Atik S, Ozen F, Göl M, Cetin A (2012). Recurrent pregnancy loss and its relation to combined parental thrombophilic gene mutations. Genet Test Mol Biomarkers, 16(4): 279–286

[33] Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S, Sadaghiani M M, Farzadi L, Ghasemzadeh A, Kafshdooz T, Sakhinia M, Sakhinia E (2013). The association between thrombophilic gene mutations and recurrent pregnancy loss. J Assist Reprod Genet, 30(10): 1353–1359

[34] Rallidis L S, Politou M, Komporozos C, Panagiotakos D B, Belessi C I, Travlou A, Lekakis J, Kremastinos D T (2008). Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost, 99(6): 1085–1089

[35] Regan L, Rai R (2002). Thrombophilia and pregnancy loss. J Reprod Immunol, 55(1-2): 163–180

[36] Sajadi S, Samiei S, Kheirandish M, Jalaifar A(2008). The association of FXIII Val34Leu polymorphism with thrombotic events in patients referring to Iranian Blood Transfusion Organization. Sci J Iran Blood Transfus Organ, 4 (4): 247–252

[37] Suzuki K, Henke J, Iwata M, Henke L, Tsuji H, Fukunaga T, Ishimoto G, Szekelyi M, Ito S (1996). Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum Genet, 98(4): 393–395

[38] Yioti G G, Panagiotou O A, Vartholomatos G A, Kolaitis N I, Pappa C N, Evangelou E, Stefaniotou M I (2013). Genetic polymorphisms associated with retinal vein occlusion: a Greek case-control study and meta-analysis. Ophthalmic Genet, 34(3): 130–139PMID:23289804

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg